AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32350529 — intervention group
Group type: EXPERIMENTAL
Intervention: No BV, TV, or VVC
Number of subjects: 303
Study 32350679 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast Conservation Therapy (BCT)
Number of subjects: 0
Study 32350679 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy with Reconstruction (M + R)
Number of subjects: 0
Study 32350901 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium plasma device
Number of subjects: 55
Study 32350915 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-cTnT)
Number of subjects: 14980
Study 32350915 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I (hs-cTnI)
Number of subjects: 14980
Study 32350915 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause death, cardiac death, myocardial infarction, stroke or systemic embolic event, major bleeding
Number of subjects: 14980
Study 32351419 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxy version of the WHODAS 2.0
Number of subjects: 77
Study 32351419 — intervention group
Group type: COMPARATOR
Intervention: Outpatients
Number of subjects: 77
Study 32351419 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-induced parkinsonism
Number of subjects: 77
Study 32351609 — intervention group
Group type: EXPERIMENTAL
Intervention: Jueyin Granules
Number of subjects: 0
Study 32351609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32351966 — intervention group
Group type: EXPERIMENTAL
Intervention: Coconut oil and caprylic acid
Number of subjects: 0
Study 32351966 — intervention group
Group type: EXPERIMENTAL
Intervention: Coconut oil and caprylic acid with glucose
Number of subjects: 0
Study 32351966 — intervention group
Group type: COMPARATOR
Intervention: Control group (without coconut oil and caprylic acid)
Number of subjects: 0
Study 32352498 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab, 240 mg intravenously every 2 weeks for 16 weeks, then 480 mg every 4 weeks until disease progression or unacceptable toxic effects.
Number of subjects: 54
Study 32352564 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillating devices (e.g., high frequency chest wall oscillation)
Number of subjects: 1114
Study 32352564 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency chest wall oscillation
Number of subjects: 1114
Study 32352564 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillating devices
Number of subjects: 1114
Study 32352564 — intervention group
Group type: COMPARATOR
Intervention: Other forms of physiotherapy (e.g., positive expiratory pressure)
Number of subjects: 1114
Study 32352586 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital medicine programme (DMP)
Number of subjects: 288
Study 32352653 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 794
Study 32352653 — intervention group
Group type: COMPARATOR
Intervention: Postmarketing data
Number of subjects: 794
Study 32353036 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert mothers (N=37)
Number of subjects: 137
Study 32353036 — intervention group
Group type: COMPARATOR
Intervention: Non-expert mothers (N=100)
Number of subjects: 137
Study 32353110 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticancer drugs (19 identified drugs including lenalidomide, pomalidomide, nilotinib, ponatinib, midostaurin, azacytidine, clofarabine, docetaxel, obinutuzumab)
Number of subjects: 11757
Study 32353318 — intervention group
Group type: EXPERIMENTAL
Intervention: Open fractures
Number of subjects: 31255
Study 32353318 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed fractures
Number of subjects: 31255
Study 32353318 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for delays
Number of subjects: 31255
Study 32353318 — intervention group
Group type: EXPERIMENTAL
Intervention: Transportation method
Number of subjects: 31255
Study 32353318 — intervention group
Group type: EXPERIMENTAL
Intervention: Fracture type
Number of subjects: 31255
Study 32353599 — intervention group
Group type: EXPERIMENTAL
Intervention: Dako PD-L1 IHC 73-10 assay
Number of subjects: 231
Study 32353599 — intervention group
Group type: COMPARATOR
Intervention: Dako PD-L1 IHC 22C3 assay
Number of subjects: 231
Study 32353599 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab (anti-PD-L1)
Number of subjects: 231
Study 32354451 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous implantable cardioverter-defibrillator (S-ICD) eligibility assessment
Number of subjects: 101
Study 32354451 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-sided S-ICD screening
Number of subjects: 101
Study 32354451 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-sided S-ICD screening
Number of subjects: 101
Study 32354451 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning prediction of S-ICD eligibility
Number of subjects: 101
Study 32354451 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of S-ICD eligibility by gender
Number of subjects: 101
Study 32354696 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning algorithm for severe sepsis prediction
Number of subjects: 17758
Study 32354716 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiautomated 2D measurements
Number of subjects: 10
Study 32354716 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric measurements
Number of subjects: 10
Study 32354716 — intervention group
Group type: COMPARATOR
Intervention: Manual 2D cross-product measurements
Number of subjects: 10
Study 32354780 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 4 mg
Number of subjects: 190
Study 32354780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 32355442 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplementation with Oculofolin containing 900 µg L-methylfolate for three months
Number of subjects: 24
Study 32355493 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab (8 mg/kg every 2 weeks)
Number of subjects: 1
Study 32355503 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) administration of alum-adjuvanted recombinant HBV vaccine
Number of subjects: 52
Study 32355503 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous (SC) administration of alum-adjuvanted recombinant HBV vaccine
Number of subjects: 52
Study 32355632 — intervention group
Group type: EXPERIMENTAL
Intervention: Allograft
Number of subjects: 0
Study 32355632 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study 32355632 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical management (NSM)
Number of subjects: 0
Study 32355775 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe WMHs (grades 5-6)
Number of subjects: 787
Study 32355775 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate WMHs (grades 3-4)
Number of subjects: 787
Study 32355775 — intervention group
Group type: EXPERIMENTAL
Intervention: Periventricular WMHs (PVWMHs)
Number of subjects: 787
Study 32355775 — intervention group
Group type: COMPARATOR
Intervention: 3-month functional outcome
Number of subjects: 787
Study 32355775 — intervention group
Group type: COMPARATOR
Intervention: Stroke recurrence
Number of subjects: 787
Study 32355775 — intervention group
Group type: COMPARATOR
Intervention: Antiplatelet therapy
Number of subjects: 787
Study 32355819 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate (DMF) + MCAO
Number of subjects: 0
Study 32355819 — intervention group
Group type: COMPARATOR
Intervention: MCAO
Number of subjects: 0
Study 32355836 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg daily
Number of subjects: 280
Study 32355836 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (VKA) with targeted INR 2-2.5
Number of subjects: 280
Study 32356159 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave ablation (MWA) of benign breast lesions (BBLs)
Number of subjects: 440
Study 32356774 — intervention group
Group type: EXPERIMENTAL
Intervention: This is Quitting (text message quit vaping program)
Number of subjects: 2600
Study 32356774 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control condition
Number of subjects: 2600
Study 32357207 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline BNP measurement
Number of subjects: 196
Study 32357207 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline BNP and ST2 measurement
Number of subjects: 196
Study 32357207 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-varying BNP measurement at 3-month intervals
Number of subjects: 196
Study 32357207 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-varying ST2 measurement at 3-month intervals
Number of subjects: 196
Study 32357207 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein, ESR, and TNF-α measurements
Number of subjects: 196
Study 32357207 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated laboratory measurements over a year
Number of subjects: 196
Study 32357901 — intervention group
Group type: EXPERIMENTAL
Intervention: Women on long-term ART
Number of subjects: 30
Study 32357901 — intervention group
Group type: COMPARATOR
Intervention: Men on long-term ART
Number of subjects: 30
Study 32357963 — intervention group
Group type: EXPERIMENTAL
Intervention: MTL-CEBPA (28-160 mg/m) administered intravenously once a week for 3 weeks followed by a rest period of 1 week per treatment cycle
Number of subjects: 38
Study 32357963 — intervention group
Group type: EXPERIMENTAL
Intervention: MTL-CEBPA
Number of subjects: 38
Study 32357963 — intervention group
Group type: EXPERIMENTAL
Intervention: MTL-CEBPA + sorafenib
Number of subjects: 38
Study 32358359 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprarenal fixation (SR) during EVAR
Number of subjects: 0
Study 32358769 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation Therapy plus treatment-as-usual (VNS + TAU)
Number of subjects: 156
Study 32358769 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 156
Study 32358807 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled dry powder mannitol
Number of subjects: 784
Study 32358807 — intervention group
Group type: COMPARATOR
Intervention: Control (very low dose of mannitol or non-respirable mannitol)
Number of subjects: 784
Study 32358807 — intervention group
Group type: COMPARATOR
Intervention: Mannitol plus dornase alfa
Number of subjects: 784
Study 32358807 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol alone
Number of subjects: 784
Study 32358807 — intervention group
Group type: COMPARATOR
Intervention: Dornase alfa alone
Number of subjects: 784
Study 32358807 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 784
Study 32358837 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1672
Study 32358837 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin plus aspirin
Number of subjects: 1672
Study 32358837 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH plus aspirin
Number of subjects: 1672
Study 32358837 — intervention group
Group type: EXPERIMENTAL
Intervention: UFH plus aspirin
Number of subjects: 1672
Study 32358887 — intervention group
Group type: EXPERIMENTAL
Intervention: Berg Balance Scale
Number of subjects: 105
Study 32358887 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity Measure for Post-Acute Care basic mobility
Number of subjects: 105
Study 32358887 — intervention group
Group type: EXPERIMENTAL
Intervention: Motricity Index
Number of subjects: 105
Study 32358887 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Independence Measure mobility subscale
Number of subjects: 105
Study 32358887 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk Control Test
Number of subjects: 105
Study 32358887 — intervention group
Group type: COMPARATOR
Intervention: Gait speed, Functional Reach Test, 6-minute Walk Test, Timed Up and Go
Number of subjects: 105
Study 32358998 — intervention group
Group type: EXPERIMENTAL
Intervention: ELF score (≥11.1)
Number of subjects: 201
Study 32358998 — intervention group
Group type: EXPERIMENTAL
Intervention: ELF score (<10.1)
Number of subjects: 201
Study 32358998 — intervention group
Group type: EXPERIMENTAL
Intervention: ELF score
Number of subjects: 201
Study 32358998 — intervention group
Group type: EXPERIMENTAL
Intervention: HA alone
Number of subjects: 201
Study 32358998 — intervention group
Group type: EXPERIMENTAL
Intervention: ELF score in strictly compensated ACLD (cACLD) patients
Number of subjects: 201
Study 32359091 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every three weeks (KEYNOTE-158)
Number of subjects: 128
Study 32359091 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg every two weeks (KEYNOTE-028)
Number of subjects: 128
Study 32359091 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events
Number of subjects: 128
Study 32359358 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM)
Number of subjects: 5625
Study 32359358 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure with reduced ejection fraction (HFrEF) with DM
Number of subjects: 5625
Study 32359358 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequate glycemic control (HbA1c ≥ 7.0%)
Number of subjects: 5625
Study 32359358 — intervention group
Group type: COMPARATOR
Intervention: Adequate glycemic control (HbA1c < 7.0%)
Number of subjects: 5625
Study 32359358 — intervention group
Group type: COMPARATOR
Intervention: Overall mortality
Number of subjects: 5625
Study 32359358 — intervention group
Group type: COMPARATOR
Intervention: In-hospital mortality
Number of subjects: 5625
Study 32359360 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel PET tracer for COX-2 measurement
Number of subjects: 0
Study 32359490 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib (600 mg twice daily)
Number of subjects: 564
Study 32359490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 564
Study 32359671 — intervention group
Group type: EXPERIMENTAL
Intervention: Civil commitment for psychiatric disorders
Number of subjects: 254
Study 32359671 — intervention group
Group type: EXPERIMENTAL
Intervention: Civil commitment for drug misuse
Number of subjects: 254
Study 32359748 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibroscan® (XL probe)
Number of subjects: 0
Study 32359748 — intervention group
Group type: COMPARATOR
Intervention: Histological examination (liver biopsy)
Number of subjects: 0
Study 32359757 — intervention group
Group type: EXPERIMENTAL
Intervention: High phase angle derived from bioelectrical impedance analysis (Nutriguard®).
Number of subjects: 2264
Study 32359931 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-sourced cooking oils (highest tertile consumption)
Number of subjects: 14305
Study 32359931 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacing animal cooking oils with 1 tablespoon/d of total plant cooking oils
Number of subjects: 14305
Study 32359931 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacing animal cooking oils with 1 tablespoon/d of other plant cooking oils
Number of subjects: 14305
Study 32359931 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut oil or salad oil consumption in replacement of animal cooking oils
Number of subjects: 14305
Study 32360168 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic faces
Number of subjects: 0
Study 32360168 — intervention group
Group type: COMPARATOR
Intervention: Dynamic objects
Number of subjects: 0
Study 32360681 — intervention group
Group type: EXPERIMENTAL
Intervention: TAMBE endograft
Number of subjects: 227
Study 32360681 — intervention group
Group type: EXPERIMENTAL
Intervention: TAMBE combined with GORE CTAG proximal thoracic stent graft
Number of subjects: 227
Study 32360681 — intervention group
Group type: COMPARATOR
Intervention: Comparison of L-TAA and E-TAA
Number of subjects: 227
Study 32360804 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric Balloon (IGB)
Number of subjects: 21
Study 32361007 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET/CT guided adaptive radiation therapy (4 Gy boost on top of 70 Gy baseline dose)
Number of subjects: 20
Study 32361007 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET/CT guided adaptive radiation therapy (78 Gy for partial metabolic response)
Number of subjects: 20
Study 32361007 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET/CT guided adaptive radiation therapy (74 Gy for complete metabolic response)
Number of subjects: 20
Study 32361755 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cabotegravir (30 mg/day)
Number of subjects: 346
Study 32361755 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabotegravir LA (400 mg every 4 weeks or 600 mg every 8 weeks)
Number of subjects: 346
Study 32361925 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary atherosclerotic plaque metrics and stenosis assessment
Number of subjects: 372
Study 32361951 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZA)
Number of subjects: 502
Study 32361951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502
Study 32362128 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) compliance measure (CCM)
Number of subjects: 0
Study 32362128 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Exposure/Response Prevention Adherence Scale for Hoarding (PEAS-H)
Number of subjects: 0
Study 32362164 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (COC)
Number of subjects: 0
Study 32362164 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term use of COC
Number of subjects: 0
Study 32363437 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal micropulse yellow laser
Number of subjects: 29
Study 32363493 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg every 2 weeks (Q2W)
Number of subjects: 909
Study 32363545 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial breast ultrasound (r-US)
Number of subjects: 148
Study 32363545 — intervention group
Group type: COMPARATOR
Intervention: Meander-like breast ultrasound (m-US)
Number of subjects: 148
Study 32363605 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety cluster
Number of subjects: 250
Study 32363605 — intervention group
Group type: EXPERIMENTAL
Intervention: Apathy/Withdrawal cluster
Number of subjects: 250
Study 32363605 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety and Circadian Disturbance clusters
Number of subjects: 250
Study 32363771 — intervention group
Group type: EXPERIMENTAL
Intervention: adalimumab-adbm
Number of subjects: 0
Study 32363771 — intervention group
Group type: COMPARATOR
Intervention: Humira
Number of subjects: 0
Study 32363771 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching from Humira to adalimumab-adbm
Number of subjects: 0
Study 32363910 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-month ART dispensing
Number of subjects: 18
Study 32363910 — intervention group
Group type: COMPARATOR
Intervention: Three-month ART dispensing
Number of subjects: 18
Study 32363949 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without CAV at 1 year and nonprogression over time
Number of subjects: 1301
Study 32363949 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without CAV at 1 year and late-onset slow CAV progression
Number of subjects: 1301
Study 32363949 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with mild CAV at 1 year and mild progression over time
Number of subjects: 1301
Study 32363949 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with mild CAV at 1 year and accelerated progression
Number of subjects: 1301
Study 32364230 — intervention group
Group type: EXPERIMENTAL
Intervention: Lard
Number of subjects: 15022
Study 32364230 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut oil
Number of subjects: 15022
Study 32364230 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean oil
Number of subjects: 15022
Study 32364230 — intervention group
Group type: EXPERIMENTAL
Intervention: Canola oil
Number of subjects: 15022
Study 32364230 — intervention group
Group type: EXPERIMENTAL
Intervention: Sesame oil
Number of subjects: 15022
Study 32364230 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined blended plant oil
Number of subjects: 15022
Study 32364230 — intervention group
Group type: COMPARATOR
Intervention: Substituting 1 tablespoon/d (8 g · 2000 kcal-1 · d-1) of soybean oil
Number of subjects: 15022
Study 32364251 — intervention group
Group type: COMPARATOR
Intervention: Alarms
Number of subjects: 5983
Study 32364251 — intervention group
Group type: COMPARATOR
Intervention: Code-word alarms
Number of subjects: 5983
Study 32364251 — intervention group
Group type: COMPARATOR
Intervention: Alarm plus desmopressin
Number of subjects: 5983
Study 32364251 — intervention group
Group type: COMPARATOR
Intervention: Alarm plus dry-bed training
Number of subjects: 5983
Study 32364508 — intervention group
Group type: EXPERIMENTAL
Intervention: App version of the distress thermometer (DT)
Number of subjects: 106
Study 32364508 — intervention group
Group type: EXPERIMENTAL
Intervention: App version of the International Physical Activity Questionnaire (IPAQ)
Number of subjects: 106
Study 32364508 — intervention group
Group type: EXPERIMENTAL
Intervention: App version of the Patient Health Questionnaire-9 (PHQ-9)
Number of subjects: 106
Study 32364508 — intervention group
Group type: EXPERIMENTAL
Intervention: App version of the PHQ (Q10)
Number of subjects: 106
Study 32364512 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergames (serious games for physical exercise) delivered to patients' homes during home study phases 2 and 3.
Number of subjects: 28
Study 32364512 — intervention group
Group type: EXPERIMENTAL
Intervention: E-coaching techniques implemented in home study phase 3.
Number of subjects: 28
Study 32364602 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction with circadian disruption (SRCD)
Number of subjects: 9
Study 32364844 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg spartalizumab intravenously, once every 4 weeks
Number of subjects: 42
Study 32364844 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1 positive patients
Number of subjects: 42
Study 32364844 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1 negative patients
Number of subjects: 42
Study 32364844 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1 ≥ 50% patients
Number of subjects: 42
Study 32365189 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV-free HRV
Number of subjects: 1612
Study 32365189 — intervention group
Group type: COMPARATOR
Intervention: HRV
Number of subjects: 1612
Study 32365189 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV-free HRV and HRV
Number of subjects: 1612